Newton Biocapital launches new NBC III fund

Newton Biocapital’s NBC III fund is designed to finance the growth and value creation of European and Japanese biotech start-ups in pre-clinical and clinical-stage that develop preventive or therapeutic treatments for chronic diseases. NBC III’s first closing involved multiple investors from NBC I, launched in 2017. NBC I took the lead in establishing investor syndicates where every euro invested was matched by a multiple from other investors.

The assets from NBC I were used to establish four academic spin-off companies – namely Epics Therapeutics, ChromaCure, AbolerIS Pharma, and NeuVasQ Biotechnologies – and one spin-out (DeuterOncology). NBC I was the lead investor for three additional early-stage and two clinical-stage companies. Furthermore, NBC I participated in three pre-IPO early-exit investments (Perseus Proteomics on Tokyo Stock Exchange MOTHERS, Sequana Medical on Euronext Brussels, and Acticor Biotech on Euronext Growth Paris).

Alain Parthoens, Managing Partner at Newton, commented: “We’re very pleased with this successful first closing of our new fund, which is made possible through the continued trust and support of our investors and most particularly through the support of SFPI/FPIM (Belgian Sovereign Fund) that served as cornerstone investor.  Our strong ties to the life sciences ecosystems of both Europe and Japan differentiates our fund from others and unlocks unique opportunities for our portfolio companies through our connections with international investors and pharmaceutical companies. By continuing to leverage the synergy between these two complimentary regions with NBC II, we will keep supporting value creation for all.”